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Introduction
Melanoma is well known for its aggressiveness 
in terms of rapid progression and poor prognosis to 
current treatments. The global incidence of cutaneous 
melanoma is increasing annually (Garbe and Leiter, 
2009). Approximately 68,130 new cases of melanoma 
diagnosed in 2010, with an estimated 8,700 mortalities 
caused by this disease in the United States (Jemal et al., 
2010). Surgical therapy is often adopted by clinicians 
to cure early stage melanoma with improved prognosis, 
while metastatic melanoma has a median survival time 
of only 6 to 9 months (Balch et al., 2001). Dacarbazine 
(DTIC) an alkylating agent is a well established treatment 
for metastatic melanoma however, DTIC as a single agent 
has no evident effect on overall survival (Agarwala, 2009). 
Combination of drugs or treatment modalities by applying 
chronomodulation approach elicits significant ongoing 
treatment and post treatment toxicity. Fortunately, in recent 
years, naturopathic medicine based drug formulation 
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functions most often as supportive or complementary 
care which involves both prevention and treatment of 
the disease with less toxicity has helped to dramatically 
decrease the rate of mortality of cancer (Loquai et al., 
2016). 
Indian herbs are popular to heal many deadly forms 
of disease such as cancer. Saffron (Crocus sativus. L) as 
a spice is an important ingredient in the Mediterranean, 
Indian and Chinese diet and has been extensively used 
in folk remedies (Giaccio, 2004). The genus Crocus 
consists of about 80 species worldwide, distributed 
from South-Western Europe, through Central Europe 
to Turkey and South-Western parts of Asia (Mathew, 
1982). Anticarcinogenic activity of saffron was reported 
in the early 1990’s and research on this subject has been 
increasing during the past decade (Salomi et al., 1991). 
Anti-cancer and anti-tumor properties of saffron have 
been studied in several cancer cell lines and animal model 
(Abdullaev, 2002; Abdullaev and Espinosa-Aguirre, 
2004). It is well reported that saffron can induce apoptosis 
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in different cancer cell lines (Tavakkol-Afshari et al., 
2008; Mousavi et al., 2009a, 2009b). Our previous studies 
shows that saffron can inhibit the growth of different 
cancer cells such as breast (Bakshi et al., 2012), pancreatic 
(Bakshi et al., 2010), and lung (Bakshi et al., 2012). It is 
also reported to be an active tumor remission agent in 
Dalton lymphoma model (Bakshi et al., 2009). Crocin is 
a major active component of saffron (Julio Escribanoa 
et al., 1996 Abe and Saito, 2000). Crocin possesses 
anti-proliferation effects on human colorectal cancer 
cells (Aung et al., 2007). This carotenoid can induce the 
alteration of gene expression profile of T24 (transitional 
cell carcinoma of bladder) cell. Anti-tumor effects of 
crocin are medicated at least in part by regulating the 
cell cycle controlling gene expression (Lv et al., 2008). 
Recently, we reported that crocin can induce the significant 
breast cancer cell (MCF-7) death by activating caspase 
signaling (Bakshi et al., 2016a) and low concentration 
of crocin can kill the cervical cancer (HEp-2) cells by 
sparing normal vero cells (Bakshi et al., 2016b). Further 
our previous study shows that saffron extract is safe in in 
vivo model (Bakshi et al., 2016a). Crocin reported to be 
an effective anti cancer agent in different cancer cells and 
tumors however, the role of crocin in in vivo melanoma 
tumor remission is not yet tested. In this study, we found 
that crocin can reduce melanoma tumor growth apparently 
by suppressing growth related parameters such as tumor 
silent period, growth delay, volume doubling time, and 
by extending mean survival time.
Materials and Methods
Cell line
B16F10 melanoma cell line was obtained from 
National Cell Centre, Pune, India. Cells were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% fetal bovine serum and 1% antibiotics (Penicillin/
streptomycin) and maintained in humidified cell incubator 
at 37°C and 5% CO2. 
Animals 
The mice (C57BL/6 strain) were selected from a 
random breed colony maintained in the animal house of 
Jawaharlal Nehru Cancer Hospital and Research Center, 
Bhopal. The mice were housed in polypropylene cages 
containing sterile paddy husk (procured locally) as 
bedding and maintained under controlled conditions of 
temperature (23 ± 20 ˚C), humidity (50 ± 5 %) and light 
and dark (10 - 14 h) respectively. The animals are fed 
with standard mice feed (formula obtained from Cancer 
Research institute, Mumbai) and filtered acidified water ad 
libitum. Mice of either sex, 6 - 8 weeks old and weighing 
22 ± 2g, were selected from the above colony for the 
experiments. All the experiment were conducted under 
the guidelines of Institutional Animal Ethical Committee.
Induction of tumor (melanoma) in mice
Cell suspension of Cell suspension of B16F10 cells 
(5x105) was implanted in C57BL/6 mice subcutaneously 
at the shaved part. The mice bearing the tumor were 
randomly divided into 2 groups with 6 mice in each group. 
The dosing was started when tumor has reached a mean 
diameter of 6 mm and this day was designated as day 0.
 
Experimental design 
Mice (n=12) were randomized into following two 
groups: Group I (positive control (vehicle) treated with 
0.2 ml normal saline) and Group II (treated with crocin 
2mg/kg of body weight) (i.p)
Tumor Growth Kinetics
The tumor size was measured every alternate day using 
vernier calipers, and the tumor volume were calculated 
(V = л/6 XD1XD2XD3 where D1, D2, and D3 are tumor 
diameters in there perpendicular planes). Tumor growth 
response was assessed from the following parameters: 
Tumor Silent period (TSP), Volume doubling time (VDT), 
Growth delay (GD), and Mean Survival time (MST).
Serum protein profiling by electrophoresis
Serum collection
The blood from normal, tumor bearing and crocin 
treated mice were obtained by cardiac puncture technique 
(Paulose et al., 1987). Approximately 0.7 to 1.0 mL 
of blood was collected in 1.5 mL eppendorf tubes and 
placed on ice. Blood was allowed to clot for 1 hr, then 
immediately centrifuged at 2,500 rpm for 10 min at 4 °C. 
Serum (0.3-0.5 ml) was separated into 100 µl aliquots and 
stored at -80 °C until proteomic analysis. 
Quantification of Protein
Serum protein quantification was done by Bradford 
method (Olson, 2016) and stock solution was prepared at 
the concentration of 1mg/mL.
Serum protein Electrophoresis
Serum samples were analyzed by using an agarose 
gel electrophoresis system (Paragon SPEP-II, Beckman, 
Fullerton, CA). Briefly, equal amount (10 μg) of serum 
protein of all groups of mice was diluted in running buffer 
(1:4 ratio) and applied to the gel, which was exposed to 
100 V for 37 min. After resolving the protein gel was 
washed in water, then gel was fixed, dried, and stained with 
ponceau stain for 25-30 minutes and destained with 7% 
acetic acid. Protein bands were scanned and quantified by 
densitometer at 600 μm (Sunita Tripathy, 2012). Different 
protein fractions were identified as per molecular weight 
as described elsewhere. Absolute values (g/dL) for the 
protein fractions were determined on the basis of the 
total protein concentration obtained by refractometry. We 
considered the proteins (albumin, alpha1, alpha 2, beta and 
gamma) band intensity of normal mice as 100%. Based on 
this we calculated percentage of proteins (albumin, alpha1, 
alpha 2, beta and gamma) from tumor bearing mice and 
crocin treated mice.
Statistical analysis 
Statistical evaluation of the data was done by 
Students’t’ test. (Graph PAD In stat software, Kyplot). 
A value of p<0.001 and p<0.05 was considered to be 
significant compare to control. 
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prognosis status of drug treatment also it measures the 
bio compatibility of drug. In our study we found that 
crocin treated mice survived 31.2 days (p<0.001) compare 
to control (26 days) (Figure 2). Data reveals that crocin 
treatment extended the survival up to 5 days and it is 
considered to be significant in clinical perspective.
Tumor volume doubling time
The tumor volume doubling time observed for control 
group was 1.6 days whereas, crocin treated group was 
found to be 1.2 days and it was not significant (p=0.001) 
(Figure 3).
Silent period
The silent period (i.e. time taken for palpable growth) 
for the control group was found to be 7.4 days whereas, 
crocin treated group was found to be 10.6 days (p<0.001) 
Results
Tumor remission by crocin
Melanoma tumor initiation, progression and remission 
were observed in control and tumor bearing mice. Our data 
reveals that crocin treatment delay the above mentioned 
parameters considerably (Figure 1A). After 21 days of 
crocin treatment reduces tumor size compare to control. 
Tumor morphology exhibits that crocin decline growth 
in dose dependent manner (Figure 1B).
Mean survival time 
MST is prominent parameter to determine the 
Figure 1A. Reduction of Tumor Burden by Crocin. 
A,Tumor bearing control mice; B, Tumor bearing mice 
treated with normal saline; C, Tumor bearing mice 
treated with crocin (2 mg/kg of body weight)
Tumor Remission Property of Crocin (2 mg/ kg of body 
weight). Values are presented as mean ± SD of two 
triplicates. Tumor was induced by transplanting B16F10 
cells (5x105) in C57BL/6 mice. Tumor bearing mice 
treated with crocin (2 mg/kg of body weight) for 21 days 
and volume of tumor was measured
Figure 2. Effect of Crocin on Mean Survival Time. Values 
are presented as mean ± SD of two triplicates. Asterisks 
indicates the significant difference compare to control 
(**: P < 0.001)
Figure 3. Effect of Crocin on Tumor Volume Doubling 
Time. Values are presented as mean ± SD of two 
triplicates. Asterisks indicates the significant difference 
compare to control (*: P < 0.05). 
Figure 4. Effect of Crocin on Tumor Silent Period. 
Values are presented as mean ± SD of two triplicates. 
Asterisks indicates the significant difference compare to 
control (**: P < 0.001). 
Figure 5. Effect of Crocin on Tumor Growth Delay. 
Values are presented as mean ± SD of two triplicates. 
Asterisks indicates the significant difference compare to 
control (**: P < 0.001). 
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Tumor growth delay
Efficacy of drug on tumor growth delay reflects their 
anti-tumor property. In this study significant growth delay 
was observed in crocin treated mice (0.804 days, p<0.001) 
compared to control (Figure 5). Data clearly evidenced 
that crocin treatment can halt the tumor initiation and 
progression.
Serum Protein Profile
Protein profile is an indicator of disease progression 
and prognosis status. In our study we found that level of 
albumin (p < 0.001), alpha 2 (p < 0.001), beta (p < 0.05), 
and gamma (p < 0.001) were reduced significantly and 
alpha1 globulin level was increased significantly p<0.001) 
in tumor bearing mice. 21 days of Crocin (2 mg/kg of 
body weight) treatment significantly reversed their levels 
near to normal values (Figure 6A). Figure 6B illustrates 
that crocin treatment reverse the altered protein profile 
by tumor induction.
 
Discussion
Complexity of tumor cellular network and its 
associated signaling is a great challenge for cancer 
researchers to understand and define effective drug 
formulation with least toxicity. Worldwide incidence of 
melanoma is increasing every year. Aggressive melanoma 
treated by DTIC with low response rate with survival 
rate of 25% and with median duration of 5 to 6 months 
(Hill et al., 1984). Emerging targeting immunotherapy is 
promising however, the host adverse reaction in response 
to this therapy in inevitable. 
Over the past few years, use of complementary and 
alternative medicine (CAM) has become integral part 
of cancer drug discovery and CAM based medication is 
popular among cancer patients in Western countries (Xu 
et al., 2006; Cui et al., 2010). Noticeably, CAM based 
medicines are widely accepted for cancer treatment in 
the United States and Europe (Wong et al., 2001; Gai et 
al., 2008). Discovery of drug formulation from natural 
dietary resources considered as safe and it is encouraged 
by World Health Organization (WHO). Dietary saffron 
(Crocus Sativus I) and its bioactive constituent crocin are 
well explored for in vitro and in vivo anti-tumor efficacy 
in different cancer models by our group (Bakshi et al., 
2009; Bakshi et al., 2012; Bakshi et al., 2016a). Angelo 
Gismondi et al. reported in vitro anti-cancer property of 
crocus sativus on B16-F10 cells (Angelo Gismondi et 
al., 2012). However, role of crocus sativus and its active 
constituent crocin on melanoma in vivo tumor initiation, 
progression and remission is not yet reported. Human to 
mouse melanoma xenograft models that recapitulate the 
phenotypes seen in the clinic provide a valuable resource 
of cells for translational research and can accelerate drug 
discovery processes for this disease (Maher et al., 2009). 
In this study, we used melanoma xenograft model by 
injecting B16F-10 cells in C57BL/6 mice and it is well 
established elsewhere. Treatment of crocin (2 mg/kg of 
body) reduces the tumor burden considerably in xenograft 
mice (Figure 1A and B). Further we measured the tumor 
growth related parameters such as mean survival time 
(MST), tumor volume doubling time (TVDT), tumor 
silent period (TSP), and tumor growth delay (TGD) in 
tumor bearing mice treated with similar dose of crocin. In 
clinical perspectives, prognosis state of disease is directly 
correlated with MST, TVDT, TSP, and TGD. Crocin 
treatment significantly enhance the MST in xenograft mice 
compare to control (Figure 2) however, precise molecular 
mechanism remains obscure. Further, tumor initiation and 
progression related parameters such as TVDT, TSP, and 
TGD were evaluated in control and crocin treated mice. 
We observed cancer prevention property of crocin by 
delaying TVDT, TGD, and enhancing TSP significantly 
(Figure 3, 4, 5). 
It is well reported that changes in the concentrations 
of serum protein were associated with cancer disease 
processes and can be indicative of health problems that 
may provide important diagnostic information (Hamad 
et al., 2009). Determination of amount of total protein, 
albumin, alpha globulin, beta globulin, and gamma 
globulin reflects actual functioning of an organism 
(Santamaria et al., 2006; Yilmaz et al., 2003). In this 
study, we measured the serum albumin, globulin (alpha1, 
alpha 2, beta, and gamma) levels in tumor bearing and 
crocin treated mice. Drastic decline in albumin, globulin 
(alpha 2, beta, and gamma) and concomitant increase in 
alpha1 globulin level in tumor bearing mice was observed 
(Figure 6 A and B). Our results is in accordance with 
Figure 6A. Effect of Crocin on Serum Protein Profile of 
Melanoma. Values are presented as mean ± SD of two 
triplicates. Asterisks indicates the significant difference 
compare to control (*: P <0.05; **: P < 0.001) 
Figure 6B. Serum Electrophoresis Profile. Blood 
collected form normal, tumor bearing, and crocin treated 
tumor bearing mice and serum separated. Equal amount 
of serum protein loaded in agarose electrophoresis 
system and stained with ponceau 
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several previous reports that have explored the alteration 
in serum protein profile of glioma patient (Hamad et al., 
2009) and lung cancer patients (Gao et al., 2005). Further, 
in this study 21 days of crocin (2mg/kg of body weight) 
treatment retrieved serum protein levels near to normal 
values. Precise molecular mechanism of crocin mediated 
immunomodulatory effect is unclear. However, it is known 
that the serum protein concentration may change under 
oxidative stress, such as the stress associated with cancer 
(Halliwell, 1997). Since crocin is well reported for anti-
oxidant property (Maryam Mashmoul et al., 2013; Yang 
Chen et al., 2008), observed immunomodulatory effect 
of crocin in the current study may be due to its reactive 
oxygen species scavenging potential. 
In conclusion, crocin treatment reduces tumor burden 
and increased MST significantly in melanoma xenograft 
mice. Tumor initiation and progression parameters such as 
TVDT, TGD, and TSP were positively regulated by crocin 
treatment. Altered serum protein profile due to tumor 
burden was significantly retrieved to normal by crocin. 
However, the detailed molecular mechanism should be 
revealed before defining the crocin based drug formulation 
for melanoma treatment.  
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